Drug Companies Update July 2008
Mergers, acquisitions & Joint Ventures
- Synthetic Blood International has changed its name to Oxygen Biotherapeutics
- Daiichi Sankyo has acquired U3 Pharma.
New Companies
- Alopexx is developing novel products for the treatment and prevention of MRSA and other serious infections.
- AMRI is a global company that provides scientific services, products and technologies.
- Armgo Pharma is developing small-molecule therapeutics, known as ‘rycals’, which target the ryanodine receptor/calcium release channel for the treatment of cardiac, muscular and neurological disorders.
- Bacilligen is a privately-owned early-stage biotechnology company developing therapies for cancer and infectious disease.
- Centrose utilizes sugars to increase the activity and decrease the toxicity of certain drugs.
- DelSite Biotechnologies is a drug delivery/biotechnology company developing novel drug delivery solutions for proteins and peptides.
- Dilafor is engaged in the development of pharmaceuticals from heparin derivatives with low anticoagulant activities.
- DSX Therapeutics is an early-stage company that investigates novel scientific treatments for sepsis.
- Gradalis is a Texas-based gene therapy developing innovative anticancer therapies involving antisense and RNAi mechanisms.
- Hepasome Pharmaceuticals develops hepatocyte-directed drug formulations for the treatment of hepatitis.
- Immunomic Therapeutics is engaged in the development of DNA vaccines based on its ‘LAMP’ technology.
- IntelGenx is a drug delivery company focused on improving existing medications by incorporating proprietary, advanced controlled-release technologies.
- MyeloRx is developing compounds derived from natural products, for the treatment of cancer and autoimmune diseases.
- Obura develops treatments for neurodegenerative disorders.
- Profectus Biosciences develops therapeutic and vaccine technologies to treat and prevent viral diseases, with focus on HIV/AIDS.
- RaQualia was spun out from Pfizer’s former central research laboratories in Japan.
- RXi is a biotechnology company focused on the development of RNAi therapeutics for the treatment of neurological and metabolic diseases and cancer.
- TGR BioScience discovers and develops therapies for oral and gastrointestinal health and skin and tissue repair.
- Valens Pharma is developing biopharmaceuticals based on a novel class of ebery metabolism agents known as PDK blockers.
